Improved GPCR ligands from nanobody tethering

Ross W. Cheloha; Fabian A. Fischer; Andrew W. Woodham; Eileen Daley; Naomi Suminski; Thomas J. Gardella; Hidde L. Ploegh

doi:10.1038/s41467-020-15884-8

Nature Communications (Apr 2020)

Improved GPCR ligands from nanobody tethering

Ross W. Cheloha,
Fabian A. Fischer,
Andrew W. Woodham,
Eileen Daley,
Naomi Suminski,
Thomas J. Gardella,
Hidde L. Ploegh

Affiliations

Ross W. Cheloha: Boston Children’s Hospital and Harvard Medical School, 1 Blackfan Circle
Fabian A. Fischer: Boston Children’s Hospital and Harvard Medical School, 1 Blackfan Circle
Andrew W. Woodham: Boston Children’s Hospital and Harvard Medical School, 1 Blackfan Circle
Eileen Daley: Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street
Naomi Suminski: Boston Children’s Hospital and Harvard Medical School, 1 Blackfan Circle
Thomas J. Gardella: Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street
Hidde L. Ploegh: Boston Children’s Hospital and Harvard Medical School, 1 Blackfan Circle

DOI: https://doi.org/10.1038/s41467-020-15884-8
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 11

Abstract

Read online

Antibodies conjugated to bioactive compounds can allow targeted delivery of therapeutics. Here the authors present a strategy for fusing nanobodies to suboptimal GPCR peptide ligands to potently and selectively activate receptors.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal